Alexa R. Runowski

Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.

J. Rasko, M. Ozelo, X. Anguela, 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year

John E. Murphy, J. Rasko, D. Rybin, 2019, Blood.